Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy – Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 12, 15, 2, 71, 34 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 2, 1, 13 and 3 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

   

Key Topics Covered:

Introduction

Report Coverage

Duchenne Muscular Dystrophy – Overview

Duchenne Muscular Dystrophy – Therapeutics Development

• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes

Duchenne Muscular Dystrophy – Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Duchenne Muscular Dystrophy – Drug Profiles

Duchenne Muscular Dystrophy – Dormant Projects

Duchenne Muscular Dystrophy – Discontinued Products

Duchenne Muscular Dystrophy – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Companies Mentioned

• AAVogen Inc
• Alpha Anomeric
• American CryoStem Corp
• Anagenesis Biotechnologies SAS
• Antisense Therapeutics Ltd
• ARMGO Pharma Inc
• Astria Therapeutics Inc
• AUM LifeTech Inc
• Autotac Bio Inc
• Avidity Biosciences Inc
• Axolo Pharma Inc
• Bayer AG
• Biogen Inc
• BioIncept LLC
• Bioleaders Corp
• BioMarin Pharmaceutical Inc
• Biophytis SA
• CANbridge Life Sciences Ltd
• Capricor Therapeutics Inc
• Chengdu Fanxi Biopharma Co Ltd
• Code Biotherapeutics Inc
• Consortium.AI
• Constant Therapeutics LLC
• CRISPR Therapeutics AG
• Cumberland Pharmaceuticals Inc
• Daiichi Sankyo Co Ltd
• DepYmed Inc
• DMD Therapeutics Inc
• DTx Pharma Inc
• Dyne Therapeutics Inc
• Dystrogen Therapeutics SA
• Edgewise Therapeutics Inc
• Editas Medicine Inc
• Eli Lilly and Co
• Eloxx Pharmaceuticals Inc
• Encell Co Ltd
• Entrada Therapeutics Inc
• Epirium Bio Inc
• EryDel SpA
• Evox Therapeutics Ltd
• FibroGen Inc
• FibroGenesis LLC
• Fulcrum Therapeutics Inc
• InnoBioscience LLC
• Italfarmaco SpA
• Ixchel Pharma LLC
• J2H Biotech
• Keros Therapeutics Inc
• KSbitugen Co Ltd
• LambdaGen Therapeutics
• Ludi Therapeutics
• Milo Biotechnology LLC
• Mitobridge Inc
• Mitochon Pharmaceuticals Inc
• MitoRx Therapeutics Ltd
• MyoGene Bio LLC
• Myos Inc
• Myosana Therapeutics Inc
• MyoTherix Inc
• Nippon Shinyaku Co Ltd
• NS Pharma Inc
• OliPass Corporation
• OMEICOS Therapeutics GmbH
• Oncocross Co Ltd
• Oncotelic Inc
• Pepgen Ltd
• PeptiDream Inc
• Pfizer Inc
• Pharmaxis Ltd
• PhaseBio Pharmaceuticals Inc
• Pliant Therapeutics Inc
• Progenitor Therapeutics Ltd
• Prothelia Inc
• PTC Therapeutics Inc
• PYC Therapeutics Ltd
• RASRx LLC
• RegenxBio Inc
• ReoStem LLC
• Ridgeline Therapeutics LLC
• Santhera Pharmaceuticals Holding AG
• Sarcomed AB
• Sarepta Therapeutics Inc
• Satellos Bioscience Inc
• Solid Biosciences Inc
• Stealth BioTherapeutics Corp
• SteroTherapeutics LLC
• Sutura Therapeutics Ltd
• Suzhou GenAssist Therapeutics Co Ltd
• Taiho Pharmaceutical Co Ltd
• Tivorsan Pharmaceuticals Inc
• Tolerion Inc
• Triplex Therapeutics Inc
• UGISense AG
• Ultragenyx Pharmaceutical Inc
• Vandria SA
• Vertex Pharmaceuticals Inc
• Vita Therapeutics Inc
• Wave Life Sciences Ltd
• Zata Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/r/btisw8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900